Conclusion
Molecular imaging holds strong promise for early and sensitive diagnosis
of thromboembolic diseases. The choice of epitopes and biomarkers for
molecular targeting, as well as the selection of imaging modalities and
their respective contrast agents, are especially important for clinical
translation. A better understanding of thrombotic diseases and their
progression will provide the clinicians with information to determine
the pharmacological treatment most suited for an individual, taking us
closer towards personalised medicine. Furthermore, the ability to
determine the success or failure of antithrombotic or fibrinolytic
treatment will also enable better decisions for invasive interventions
to be performed. Therefore, molecular imaging of thrombi has an enormous
potential to provide benefits for patients suffering from thromboembolic
diseases.